Fundraising FoxOcudyne
Brooklyn Park, US · Founded 2013 · Delaware corporation
Find your way into Ocudyne
Sign up to see every warm intro you have to Ocudyne
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ocudyne team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OcuDyne develops an investigational ophthalmic device called OPTiC that is currently undergoing clinical trials in the United States. The company operates in the medical device and healthcare sector, focused on eye care applications.
Founders & leadership
JF
Jeff FrancoCEO
JN
Jim NessCFO
MC
Mike CalhounVP Research and Development
LW
Luana WilburVP Clinical & Regulatory Affairs
Board
JS
Joseph SmithBoard director
JT
Jonathan TalamoBoard director
Reported raises · per SEC filings
Form D private placements$9.1M disclosed across 4 rounds · 2016–2025
▶$5.7MraisedMar 2025 · 8 investors · Other Health CareRule 506(b)
▶$5.7MraisedMar 2025 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph SmithDirector
- Jeffrey FrancoExecutive Officer, Director
- Jonathan TalamoDirector
- Offering amount
- $12.1M
- Amount sold
- $5.7M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2019 · 1 investors · Other Health CareRule 506(b)
▶$2MraisedFeb 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey FrancoExecutive Officer, Director
- Robert AtkinsonExecutive Officer, Director
- Joseph SmithDirector
- Offering amount
- $3.2M
- Amount sold
- $2M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$886.5KraisedAug 2017 · 6 investors · Other Health CareRule 506(b)
▶$886.5KraisedAug 2017 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph SmithDirector
- Jeffrey FrancoExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $886.5K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$463KraisedOct 2016 · 5 investors · Other Health CareRule 506(b)
▶$463KraisedOct 2016 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph M. SmithDirector
- Jeffrey FrancoExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $463K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Ocular TherapeutixOcular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.
OculisOculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments. It conducts formulation, process, and analytical development to advance drug candidates from early research through later development stages.
Companies working in the same space as Ocudyne.
Frequently asked questions
- What does Ocudyne do?
- OcuDyne develops an investigational ophthalmic device called OPTiC that is currently undergoing clinical trials in the United States. The company operates in the medical device and healthcare sector, focused on eye care applications.
- How much funding has Ocudyne raised?
- Ocudyne has disclosed $9.1M raised across 4 rounds.
- Where is Ocudyne headquartered?
- Ocudyne is headquartered in Brooklyn Park, US.